Schrodinger, Inc. shares rise 1.90% intraday after Certara's Simcyp Simulator receives EMA qualification.

Schrodinger, Inc. rose 1.90% in intraday trading, with Certara, Inc. announcing that the European Medicines Agency (EMA) has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU. This qualification allows sponsors to use the Simcyp Simulator to assess drug-drug interaction (DDI) risk without needing to re-establish the platform's credibility for the specified context of use (COU) scenarios.